Merck & Co., Inc. has received clearance for Winrevair (sotatercept) from the European Commission (EC) exactly five months after it was approved in the US, where the commercial launch to date has exceeded expectations. The firm is planning to launch Winrevair in European markets later this year, likely starting in Germany.
Key Takeaways
-
The European Commission approved Winrevair (sotatercept) for pulmonary arterial hypertension, five months after it won US FDA approval.
Merck said on 26 August that the EC approved Winrevair for use in combination with other pulmonary arterial hypertension (PAH)...
